title: THE NEED FOR HBV GENOTYPING: A COST-EFFICIENT APPROACH.
abstract: The outcome of chronic HBV infection is variable; approximately one half of individuals transition to an inactive carrier state, 30% progress to cirrhosis, and the remainder to chronic hepatitis. Ten different HBV genotypes and many subtypes have been identified with distinct geographical distributions. Over the years, a lot of studies presented the efficiency of different genotyping methods; for this reason we aimed to present a cost efficient genotyping diagnosis algorithm of CHB infected patients, especially useful to identify those at risk of disease progression and determine optimal anti-viral therapy as useful instrument for physicians.
authors.forename: A S
authors.initials: AS
authors.lastname: Luca
authors.forename: Ramona Gabriela
authors.initials: RG
authors.lastname: Ursu
authors.forename: Teodora
authors.initials: T
authors.lastname: Teuşan
authors.forename: Cătălina Mihaela
authors.initials: CM
authors.lastname: Luca
authors.forename: Claudia Elena
authors.initials: CE
authors.lastname: Pleşca
authors.forename: Luminiţa Smaranda
authors.initials: LS
authors.lastname: Iancu
mesh_terms: D000998:Antiviral Agents / Q000191:economics / Q000627:therapeutic use; D003362:Cost-Benefit Analysis; D004279:DNA, Viral / Q000235:genetics*; D018450:Disease Progression; D005838:Genotype; D060005:Genotyping Techniques / Q000191:economics*; D006514:Hepatitis B Surface Antigens / Q000235:genetics*; D019694:Hepatitis B, Chronic / Q000188:drug therapy / Q000191:economics* / Q000235:genetics*; D006801:Humans; D007372:Interferons / Q000191:economics / Q000627:therapeutic use; D012383:Romania; D016896:Treatment Outcome
chemical_list: D000998:Antiviral Agents; D004279:DNA, Viral; D006514:Hepatitis B Surface Antigens; D007372:Interferons